Press Release

Drug-Eluting Stent Prices Experiencing Downward Pressure from Canadian Health Care System


October 18th, 2010

Global Information, Inc. would like to present a new market research report "Canadian Markets for Interventional Cardiology Devices 2011" by Millennium Research Group.

The drug-eluting stent segment is the most lucrative out of all the interventional cardiology device markets, worth $55 million as of 2010. However, the Canadian interventional cardiology device market is a highly dynamic and competitive market with only a small number of large competitors vying for market share. There are many barriers to entry that do not allow device manufacturers to easily enter the Canadian health system.

Perhaps one of the key determinants of device adoption in Canada is price due to the way the health care system is set up. The government dictates a set budget to facilities that must be used to purchase devices in a way that enables universal access for Canadian citizens to health care. What this means is that generally the most advanced, and most likely premium-priced devices, are not utilized by hospitals and facilities because they cannot afford to purchase and still provide treatment to all patients. Not only does this set a limit on revenues for the Canadian interventional cardiology device market, but it also hinders manufacturers from entering or launching new products in the Canadian market. Manufacturers view the Canadian interventional cardiology device market as not cost effective.

"Growth in drug-eluting stent procedure volumes  which will occur at the expense of bare-metal stent procedures  will be sustained through 2015," according to Adrienne Ma, MRG Analyst. "Interventional cardiologists interviewed by MRG [say], drug-eluting stent prices are falling dramatically in Canada because of competitive pricing pressures caused by manufacturers fighting to bolster their market share by maintaining and establishing new contracts with hospitals. The upside to the pricing declines is that facilities are able to afford more drug-eluting stents within the same constrained budget that is applied by the Canadian public health care system."


Global Information Inc.(GII) - specializing in market research provision for the vertical industries, GII offers expert independent recommendations of publications from hundreds of the globe's leading market research firms.

Product Code : 134502